Atyr PHARMA (ATYR) Competitors

Atyr PHARMA (NASDAQ:ATYR) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.

Does the MarketBeat Community believe in ATYR or APGE?

Apogee Therapeutics received 13 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 96.55% of users gave Apogee Therapeutics an outperform vote.

Company	Underperform	Outperform
Atyr PHARMA	Outperform Votes 15 100.00%	Underperform Votes No Votes
Apogee Therapeutics	Outperform Votes 28 96.55%	Underperform Votes 1 3.45%

Which has more risk & volatility, ATYR or APGE?

Atyr PHARMA has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Does the media prefer ATYR or APGE?

In the previous week, Atyr PHARMA had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Atyr PHARMA and 4 mentions for Apogee Therapeutics. Atyr PHARMA's average media sentiment score of 0.60 beat Apogee Therapeutics' score of 0.55 indicating that Atyr PHARMA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atyr PHARMA	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ATYR or APGE?

Atyr PHARMA currently has a consensus price target of $18.60, indicating a potential upside of 245.08%. Apogee Therapeutics has a consensus price target of $94.60, indicating a potential upside of 122.90%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, equities research analysts plainly believe Atyr PHARMA is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Apogee Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings and valuation, ATYR or APGE?

Atyr PHARMA has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Atyr PHARMA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$235K	2,041.41	-$50.39M	-$0.81	-6.65
Apogee Therapeutics	N/A	N/A	-$83.99M	-$3.60	-11.79

Do institutionals & insiders have more ownership in ATYR or APGE?

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is ATYR or APGE more profitable?

Apogee Therapeutics' return on equity of -21.81% beat Atyr PHARMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
Apogee Therapeutics	N/A	-21.81%	-20.94%

Summary

Atyr PHARMA beats Apogee Therapeutics on 11 of the 17 factors compared between the two stocks.